Literature DB >> 21221848

The clinical significance of coagulation and the inflammatory response in autoimmunity.

Benjamín Rubio-Jurado1, Paulina Iñiguez-Franco, Pedro A Reyes, Gustavo Robles, Mario Salazar-Páramo, Guadalupe Zavala-Cerna, Carlos Riebeling, Arnulfo Nava.   

Abstract

Maintenance of normal blood flow requires equilibrium between procoagulant and anticoagulant factors; occasionally, procoagulant activity predominates, leading to clot formation; frequently, tissue damage is the triggering factor. Hereditary factors, primary or acquired, play a role in the development of thrombosis. Primary thrombophilia is associated with hereditary factors, which promote hypercoagulability because natural anticoagulants are not exerting their activity. On the other hand, acquired thrombophilia may occur associated to autoimmune diseases, cancer, surgical procedures, pregnancy, postpartum period, and obesity. Activation of the coagulation system is characterized by the co-participation of inflammatory response components, factors related to the subjacent disease, and other procoagulant factors. The study of patients with thrombosis should include both inflammatory and autoimmune response markers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21221848     DOI: 10.1007/s12016-010-8240-0

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  71 in total

Review 1.  Platelets as immune cells: bridging inflammation and cardiovascular disease.

Authors:  Philipp von Hundelshausen; Christian Weber
Journal:  Circ Res       Date:  2007-01-05       Impact factor: 17.367

Review 2.  Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome.

Authors:  Rolf T Urbanus; Ronald H M W Derksen; Philip G de Groot
Journal:  Blood Rev       Date:  2007-10-25       Impact factor: 8.250

Review 3.  Antiprothrombin antibody testing: detection and clinical utility.

Authors:  Kenji Oku; Tatsuya Atsumi; Olga Amengual; Takao Koike
Journal:  Semin Thromb Hemost       Date:  2008-09-23       Impact factor: 4.180

Review 4.  Deep vein thrombosis.

Authors:  Paul A Kyrle; Sabine Eichinger
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

Review 5.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

Review 6.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

Review 7.  A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis.

Authors:  H Wolinsky
Journal:  Circ Res       Date:  1980-09       Impact factor: 17.367

Review 8.  Biological effects of C1 inhibitor.

Authors:  Alvin E Davis
Journal:  Drug News Perspect       Date:  2004-09

9.  Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.

Authors:  L R Lopez; M Salazar-Paramo; C Palafox-Sanchez; B L Hurley; E Matsuura; I Garcia-De La Torre
Journal:  Lupus       Date:  2006       Impact factor: 2.911

10.  beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

Authors:  H Bas de Laat; Ronald H W M Derksen; Rolf T Urbanus; Mark Roest; Philip G de Groot
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

View more
  2 in total

Review 1.  Thromboembolic complications and cardiovascular events associated with celiac disease.

Authors:  Fotios S Fousekis; Eleni T Beka; Ioannis V Mitselos; Haralampos Milionis; Dimitrios K Christodoulou
Journal:  Ir J Med Sci       Date:  2020-07-20       Impact factor: 1.568

2.  The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients.

Authors:  Mark Jaradeh; Nausheen Baig; Emily Bontekoe; Mirjana Mitrovic; Darko Antic; Debra Hoppensteadt; Bulent Kantarcioglu; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.